DhdR Transcriptional Regulator Biosensor for D-2-HG Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting D-2-hydroxyglutarate (D-2-HG) are time-consuming, labor-intensive, and require derivatization, limiting the development of diagnostic and therapeutic techniques for D-2-HGA and related cancers.
Innovation Solution
A transcriptional regulator, DhdR, specifically responding to D-2-HG is developed, which binds to its upstream promoter region and induces conformational changes upon D-2-HG presence, used in a biosensor system to detect D-2-HG concentrations through luminescence signal changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If GC-MS/MS or LC-MS/MS is used to detect D-2-HG, then measurement precision is improved, but loss of time and productivity deteriorate due to time-consuming procedures
Solution Approach 1:
The patent replaces complex mechanical/chemical separation systems (GC-MS/MS, LC-MS/MS) with a biological recognition system. The transcriptional regulator DhdR specifically binds to D-2-HG, and this binding event is transduced into a luminescence signal through Alpha technology, eliminating the need for time-consuming chromatographic separation and derivatization steps while maintaining detection accuracy.
Solution Approach 2:
The patent introduces a transcriptional regulator DhdR as an intermediary between D-2-HG and the detection system. DhdR acts as a specific biorecognition element that binds to D-2-HG and triggers a luminescence response via Alpha technology, serving as a bridge that converts chemical binding into a measurable optical signal without requiring complex instrumental analysis.
2Measurement precision
If derivatization reagents are used to distinguish D-2-HG from L-2-HG, then measurement precision is improved, but device complexity and ease of operation worsen
Solution Approach 1:
The patent applies local quality by engineering the transcriptional regulator DhdR with specific structural characteristics that confer enantioselectivity. The ligand binding domain of DhdR has a specific three-dimensional structure that selectively accommodates D-2-HG over L-2-HG, providing chiral discrimination at the molecular level without requiring external derivatization reagents or complex separation systems.
3Measurement precision
If traditional detection methods are used, then measurement precision is improved, but ease of operation and productivity deteriorate due to labor-intensive procedures
Solution Approach 1:
The patent implements self-service by designing a biosensor system that automatically performs detection without manual intervention. The transcriptional regulator DhdR autonomously binds to D-2-HG in the sample, and the Alpha technology system automatically transduces this binding event into a luminescence signal that can be read directly, eliminating the need for manual derivatization, injection, and complex data processing required by traditional methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DhdR-based biosensor provides a simple, highly specific, and sensitive method for detecting D-2-HG in various biological samples, consistent with traditional LC-MS/MS results, with broad applications in diagnosing D-2-HG-related diseases and developing targeted therapies.
Implementation Method 1
When D-2-HG is present, it will combine with the transcriptional regulator DhdR and induce the conformational changes of DhdR, resulting in the dissociation of the transcriptional regulator DhdR and the target DNA acted by the transcriptional regulator DhdR
Implementation Method 2
At present, it has been reported that transcriptional regulators are used as biorecognition elements in combination with Alpha technology to develop biosensors for high-sensitivity detection of uric acid and oxytetracycline
Data Source
AI summary
A transcriptional regulator specifically responding to D-2-hydroxyglutarate (D-2-HG) and its application in the biological detection of D-2-HG. Wherein the transcriptional regulator is named DhdR and the nucleotide sequence is shown as SEQ ID NO: 1. The D-2-HG biosensors BD2HG-0 and BD2HG-1 are constructed using the transcriptional regulator DhdR and can detect biological samples containing D-2-HG.